Literature DB >> 16167001

New agents in the treatment of acute myeloid leukemia: a snapshot of signal transduction modulation.

Ting Bao1, B Douglas Smith, Judith E Karp.   

Abstract

Acute myeloid leukemia continues to present formidable treatment challenges as there is not yet a "standard approach" that reliably and safely cures the majority of adults with this disorder. Efforts to better understand the basic cellular and molecular biology of acute myeloid leukemia have unveiled a complicated network of signaling pathways that support the cancer cells. Disrupting the transmission of the cells' survival signals offers appealing targets for drug development. This review will focus on several exciting components of these pathways and the agents targeting these pathways that are entering clinical trials.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16167001

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


  3 in total

Review 1.  Exploiting cellular pathways to develop new treatment strategies for AML.

Authors:  Amir T Fathi; Steven Grant; Judith E Karp
Journal:  Cancer Treat Rev       Date:  2010-01-06       Impact factor: 12.111

Review 2.  New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines.

Authors:  Amir T Fathi; Judith E Karp
Journal:  Curr Oncol Rep       Date:  2009-09       Impact factor: 5.075

3.  Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.

Authors:  Amir T Fathi; Traci M Blonquist; Daniela Hernandez; Philip C Amrein; Karen K Ballen; Malgorzata McMasters; David E Avigan; Robin Joyce; Emma K Logan; Gabriela Hobbs; Andrew M Brunner; Christelle Joseph; Ashley M Perry; Meghan Burke; Tanya Behnan; Julia Foster; Meghan K Bergeron; Jenna A Moran; Aura Y Ramos; Tina T Som; Jessica Rae; Kaitlyn M Fishman; Kristin L McGregor; Christine Connolly; Donna S Neuberg; Mark J Levis
Journal:  Cancer       Date:  2017-09-28       Impact factor: 6.860

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.